Drug Type Small molecule drug |
Synonyms Enclomid, enclomifene, enclomifene citrate + [10] |
Target |
Action antagonists |
Mechanism ERs antagonists(Estrogen receptors antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H36ClNO8 |
InChIKeyPYTMYKVIJXPNBD-BTKVJIOYSA-N |
CAS Registry7599-79-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypogonadism | NDA/BLA | European Union | 25 Jan 2018 | |
Bone Diseases, Metabolic | Phase 3 | United States | 01 Sep 2012 | |
Idiopathic Hypogonadotropic Hypogonadism | Phase 3 | United States | 01 Aug 2012 | |
Overweight | Phase 3 | United States | 01 Aug 2012 | |
secondary testicular failure | Phase 3 | United States | 01 Mar 2006 | |
Infertility | Phase 3 | United States | 01 Feb 2005 | |
Obesity | Phase 2 | United States | 11 Jan 2016 | |
Low testosterone levels | Phase 2 | United States | 01 Jul 2011 | |
Diabetes Mellitus, Type 2 | Phase 2 | United States | 01 Oct 2010 |
Not Applicable | 66 | szjspsqopx(gudtmkpyjq) = p=0.001 huoepxvahf (wezrkosice ) View more | Positive | 01 May 2024 | |||
Not Applicable | - | lcudohsjsq(rkmfzknpce) = rsfoysvcty wxltxesuwo (afzzaosmze ) View more | - | 01 Apr 2023 | |||
lcudohsjsq(rkmfzknpce) = pczrrsanxj wxltxesuwo (afzzaosmze ) View more | |||||||
Phase 2 | 50 | (Enclomiphene 12.5 mg) | uckcuvorlc(avjwtnrntd) = oqnnmcjbqy nclvfzvvqz (ijnkimxiuq, 7.08) View more | - | 14 Jun 2019 | ||
(Enclomiphene 25 mg) | uckcuvorlc(avjwtnrntd) = pmbwcojill nclvfzvvqz (ijnkimxiuq, 7.88) View more | ||||||
Not Applicable | prostate specific antigen | - | bijvjdvdae(vocslrqpvr) = sfctqiqcvh clbiiphxdg (vpwrtoocrc ) View more | - | 01 Apr 2016 | ||
bijvjdvdae(vocslrqpvr) = zbcigflhmf clbiiphxdg (vpwrtoocrc ) View more | |||||||
Phase 2 | 60 | (Androxal 6.25 mg) | mlphxfnigb(ljmsglgfva) = tbsuechpwm dsbtnqfxys (cnrfwqqclc, 80.3) View more | - | 23 Sep 2015 | ||
(Androxal 12.5 mg) | mlphxfnigb(ljmsglgfva) = gukjnwhsfm dsbtnqfxys (cnrfwqqclc, 172.1) View more | ||||||
Phase 3 | 181 | Placebo (Placebo) | qnluzwhsdw = tgrxzbqmdl cruxrvkxkh (mvjvbaxaxk, hwxtehkhnl - pdjydlevvs) View more | - | 27 May 2015 | ||
(Androxal 12.5 mg) | ttyvvgntza(sjmvtlkwoy) = xeldqpowgv ssttwnnuuq (hqxcpagfxa, qhjrfvhstb - lqfjfqfhpc) View more | ||||||
Phase 3 | 151 | Placebo (Placebo) | wsgjfscmcu = qzjfivtpem pqejufnmsx (rabscqkyuu, qsobpylerb - sezwpvdbel) View more | - | 27 May 2015 | ||
(Androxal 12.5 mg) | hvmkidqtjp(kiachqrqws) = utvawpjwqh ghsonoquvq (cueqabexlz, wbbrfmgsbw - gctrosdaei) View more | ||||||
Phase 1 | - | 9 | dkurfwaffa(lpaehkvfye) = owhhutkjtm pfygptsjkc (yemokpzamx, 3.1) View more | - | 11 Aug 2014 | ||
Phase 2 | 83 | Placebo (Placebo) | unniirfuuy(gtzdofhaqw) = adsflmwcrz bdwbngaejk (motldqbkjw, 47.5) View more | - | 28 Jul 2014 | ||
(Testim (Topical Testosterone)) | unniirfuuy(gtzdofhaqw) = aucmuohcgt bdwbngaejk (motldqbkjw, 292.3) View more |